Skip to main content
. 2021 Jan 19;11(1):140. doi: 10.3390/diagnostics11010140

Figure 1.

Figure 1

a Sensitivity analysis assessing the potential impact of cost-sharing of POC GeneXpert instruments with TB diagnostics. As POC VL is not yet rolled out, the potential for cost-sharing equipment with other diseases remains uncertain. Therefore, we present costs assuming 25%, 50%, 75%, and 100% of the equipment is used for POC VL testing, with the remaining absorbed by other diagnostics programs like TB.